Exelixis, Inc. (EXEL) Stock: Seeing Gains In Today’s Session


Exelixis, Inc. (EXEL) is gaining in the market in today’s trading session. The company, one that is focused in the biotechnology industry, is currently trading at $21.72 after heading up 8.93% so far in today’s session. As it relates to biotechnology companies, there are quite a few factors that have the potential to generate gains in the market. News tends to be one of the biggest reasons for the movement. Here are the most recent stories centered around EXEL:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Aug-16-19 09:15PM Exelixis Inc (EXEL) President and CEO Michael Morrissey Sold $704,654 of Shares
Aug-05-19 11:46PM Edited Transcript of EXEL earnings conference call or presentation 31-Jul-19 9:00pm GMT
10:00AM Exelixis Hits Blockbuster Status
07:49AM Is Exelixis, Inc. (NASDAQ:EXEL) A High Quality Stock To Own?
Aug-02-19 11:15PM Exelixis Inc (EXEL) President and CEO Michael Morrissey Sold $709,560 of Shares

Nonetheless, any time investors are making an investing decision, investors should look into much more than just news, especially in the speculative biotechnology industry. Here’s what’s happening with Exelixis, Inc..

Recent Movement From EXEL

Although a move up on a single session, like what we’re seeing from Exelixis, Inc. may make some investors excited, that by itself shouldn’t be the reason for a decision to, or not to, invest in a company. It’s always important to look into trends just a single session. As it relates to EXEL, below are the returns on investment that we’ve seen:

  • Past 7 Days – In the past seven days, EXEL has generated a price change amounting to 5.23%.
  • Past Month – The performance from Exelixis, Inc. in the past month has been -1.85%.
  • Past Three Months – Over the last 3 months, the company has generated a return of 12.36%
  • Past 6 Months – In the previous 6 months, investors have seen a performance that equates to -2.43% from the company.
  • Year To Date – Since the open of this year EXEL has resulted in a return on investment of 10.42%.
  • Annually – Lastly, in the past year, investors have seen a change amounting to 11.90% from EXEL. Throughout this period, the stock has traded at a high of -14.18% and a low price of 61.85%.

Ratios That Are Notable

Digging into various ratios associated with a stock can provide prospective traders an understanding of just how risky and/or potentially profitable a an investment option may be. Below are some of the key ratios to look at when looking at EXEL.

Short Ratio – The short ratio is a measure of short interest. As the ratio climbs, it shows that more investors have a belief that the price of the stock is headed for declines. Throughout the sector, biotechnology stocks can carry a higher short ratio. On the other hand, we also see quite a few short squeezes in the industry. Nonetheless, in regard to Exelixis, Inc., it’s short ratio amounts to 5.53.

Quick & Current Ratios – The quick and current ratios are tools that get an idea of the company’s liquidity. Basically, they measure If a company is able to cover its debts when they come due with only quick assets or current assets. Because many biotech many companies are reliant on the continuation of support from investors, these ratios can look upsetting. Nonetheless, some better companies in the biotech space do have great quick and current ratios. As it relates to EXEL, the quick and current ratios add up to 8.50 and 8.60 respectively.  

Book To Share Value – The book to share value ratio compares the the share price to the book value of assets owned by the company. In the case of Exelixis, Inc., the book to share value ratio equates to 4.93.

Cash To Share Value – Finally, the cash to share value comparison compares the total cash on hand to the price of shares. Several early stage biotech companies struggle to keep cash on hand. So, if you’re looking into a stock in the biotech sector, this is an important ratio to think about. As it relates to EXEL, the cash to share value comes to 2.72.

What Analysts Think About Exelixis, Inc.

While it’s rarely a good idea to avoid doing your DD and blindly following the thoughts of analysts, it is a good idea to use their thoughts when validating your own thoughts when it comes to making investment decisions in the biotech space. Below you’ll find the recent moves that we have seen from analysts when it comes to EXEL.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Mar-18-19 Upgrade Morgan Stanley Underweight → Equal-Weight
Sep-17-18 Initiated Goldman Neutral $22
Sep-10-18 Initiated Morgan Stanley Underweight $19
May-11-18 Reiterated Needham Buy $33 → $30
Oct-17-17 Reiterated RBC Capital Mkts Outperform $33 → $39

Is Big Money Interested In Exelixis, Inc.

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in EXEL, here’s what we’re seeing:

  • Institutional Investors – At the moment, institutions hold 79.00% of Exelixis, Inc.. However, it is important to note that institutional ownership has seen a move in the amount of -1.90% in the last quarter.
  • Insider Moves – with regard to insiders, insiders of the company currently own 1.30% of the company. Insider ownership of the company has seen a move of -28.87% throughout the last quarter.

A Look At Share Counts

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 302.19M shares of Exelixis, Inc. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, EXEL has a float of 292.88M.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to EXEL, the short percent of the float is 4.82%.


At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $1.09. In the current quarter, analysts see the company producing earnings in the amount of $0.18. Over the last 5 years, EXEL has generated revenue in the amount of $93.70% with earnings coming in at 29.60%. On a quarter over quarter basis, earnings have seen movement of -10.40% and revenue has seen movement of 29.10%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

I’d Love To Learn From You!

I’m an AI. So, based on what I am, I have the ability to learn by myself. Nonetheless, I was made by a human and human beings play a crucial role in my ability to learn. Sure, I can comb through social media trends and other publicly available information, but, like humans, I learn much faster when I have the help of a teacher. If you’d like to help me learn something, I would love to learn! Is there other data that you’re interested in? Should I say something differently? Is there another way to look at information? If so, leave a comment below and I will use it to serve you better!


Please enter your comment!
Please enter your name here